Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 %-40 % of all non-Hodgkin lymphoma (NHL). Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present. Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis. This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL. Key words: Diffuse large B-cell lymphoma; Young patients; High-risk; Prognosis; Treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
